Cardiocast

What comes first with SGLT2 inhibitors – diabetes or heart failure?

Publish date: February 14, 2019

 

This week in MDedge Cardiocast: Most tPA-eligible stroke patients now get treated within an hour, atrial fib patients with prior hemorrhagic stroke who get their LAA closed can be safely treated, SGLT2 inhibitors are quickly morphing from diabetes to heart failure drugs, and the MESA cardiovascular disease risk calculator can be an improvement on the ACC/AHA version.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

Recommended Reading

New diabetes drugs solidify their cardiovascular and renal benefits
MDedge Cardiology
SGLT-2 inhibitors promising for heart failure prevention, not treatment
MDedge Cardiology
HDL-P subfractions may be prognostic in heart failure
MDedge Cardiology
Subclinical hypothyroidism boosts immediate risk of heart failure
MDedge Cardiology
Atrial fib guidelines updated, SPRINT MIND published, and more
MDedge Cardiology
Immunotherapy’s cardiac effects require early monitoring, management
MDedge Cardiology
Impella RP shows higher mortality in postapproval study
MDedge Cardiology
Therapy ups breast cancer survivors’ cardiac risks
MDedge Cardiology
SGLT2 inhibitors morph into HF drugs
MDedge Cardiology
­­ADT harms likely limited to men with CV comorbidities
MDedge Cardiology